Literature DB >> 20575596

Hepatocyte growth factor and chronic hepatitis C.

E Marín-Serrano1, C Rodríguez-Ramos, F Díaz-García, L Martín-Herrera, C Fernández-Gutiérrez-Del-Alamo, J A Girón-González.   

Abstract

OBJECTIVE: The hepatocyte growth factor (HGF) is a pleiotropic cytokine produced by hepatic stellate cells and implicated in liver regeneration and fibrosis. Serum levels of HGF vary in liver diseases, reflecting hepatic damage and hepatocellular dysfunction. In this study, serum levels of HGF and the relationship between HGF and biochemical, histological and virological data, have been analysed in patients suffering from chronic hepatitis C (CHC). PATIENTS AND METHODS: Serum HGF concentration was measured by ELISA in sandwich in 45 patients with CHC. Correlation between HGF levels and histological (necroinflammatory activity and fibrosis score) and biochemical (transaminases, prothrombin activity, albumin, bilirubin), or virological (hepatitis C virus load) parameters was analyzed. Serum HGF concentration was also studied in a subgroup of the original sample treated with interferon and ribavirin.
RESULTS: Sserum HGF concentrations of patients with CHC were significantly higher than those detected in healthy controls. Patients with significant fibrosis (F > or = 2) had a significantly older age, lower count of platelets and higher values of AST, GGT and HGF, than those patients with a fibrosis score F < 2. HGF concentration was identified by multivariate analysis as the only independent factor associated with significant fibrosis. Moreover, area under receiver operating curve, using HCG levels, showed similar values to those of previously validated non-invasive indexes of fibrosis. However, levels of HGF did not show a significant decrease in patients with a sustained response to anti-virus C therapy.
CONCLUSION: Serum HGF concentration correlates with fibrosis score in patients with CHC, but is insensitive to monitor changes induced by anti-virus C therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20575596     DOI: 10.4321/s1130-01082010000600004

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  6 in total

Review 1.  Hepatocyte growth factor (HGF) and hemodialysis: physiopathology and clinical implications.

Authors:  Carmelo Libetta; Pasquale Esposito; Claudia Martinelli; Fabrizio Grosjean; Marilena Gregorini; Teresa Rampino; Antonio Dal Canton
Journal:  Clin Exp Nephrol       Date:  2015-12-16       Impact factor: 2.801

2.  Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs.

Authors:  Sara Cuesta-Sancho; José-Antonio Girón-González; Mercedes Márquez-Coello; Ana Arizcorreta; María Rodríguez-Pardo; Francisco Illanes-Álvarez; Denisse Márquez
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

3.  Effects of HGF gene polymorphisms and protein expression on transhepatic arterial chemotherapeutic embolism efficacy and prognosis in patients with primary liver cancer.

Authors:  Hai-Yong Chen; Yao-Min Chen; Jian Wu; Fu-Chun Yang; Zhen Lv; Yi-Gang Qian; Shu-Sen Zheng
Journal:  Onco Targets Ther       Date:  2017-02-13       Impact factor: 4.147

4.  The Effect of Treatment-Induced Viral Eradication on Cytokine and Growth Factor Expression in Chronic Hepatitis C.

Authors:  Leona Radmanić; Kristian Bodulić; Petra Šimičić; Adriana Vince; Snježana Židovec Lepej
Journal:  Viruses       Date:  2022-07-24       Impact factor: 5.818

5.  Proinflammatory Cytokines (IL-1α, IL-6) and Hepatocyte Growth Factor in Patients with Alcoholic Liver Cirrhosis.

Authors:  Andrzej Prystupa; Paweł Kiciński; Jarosław Sak; Anna Boguszewska-Czubara; Anna Toruń-Jurkowska; Wojciech Załuska
Journal:  Gastroenterol Res Pract       Date:  2015-08-20       Impact factor: 2.260

6.  Development of a model based on biochemical, real‑time tissue elastography and ultrasound data for the staging of liver fibrosis and cirrhosis in patients with chronic hepatitis B.

Authors:  Shi-Hao Xu; Qiao Li; Yuan-Ping Hu; Li Ying
Journal:  Mol Med Rep       Date:  2016-08-26       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.